EverHint – Momentum Swing — Volatile High Beta for Mar 10, 2026 – 6 Signals – Healthcare Leads (3)

What This Signal Is (Quick)

Volatile High Beta is a momentum swing trading strategy focused on High volatility stocks (60%+) - for risk-tolerant traders.

Signal Type: Breakout (momentum continuation)

What Makes This Signal:

• Stock showing strong momentum near or at highs
• Increased volume confirms institutional interest
• Breaking out or consolidating near resistance
• High volatility stocks (60%+) - for risk-tolerant traders

Ideal For: Risk-tolerant traders comfortable with high volatility and large price swings

Key Criteria:

• Strong RSI momentum (configurable thresholds)

• Volume surge above average

• Price momentum confirmation

• Minimum ADV: $25M+ (varies by variant)

• Earnings buffer: 7 days pre/post earnings

• Variant-specific filters applied

Holding Period: 1-4 weeks
Risk Level: Medium-High

How We Ranked Today

Ranked by composite momentum score (higher = stronger momentum)

📊 Momentum Swing — Volatile High Beta Signals (6 Total)

Ranked by score:

Field Notes

Sector concentration: Healthcare (3), Industrials (2), Basic Materials (1)

Insider selling: AMPX (Amprius Technologies, Inc., $-12.4M), AGX (Argan, Inc., $-7.2M)

Near-term earnings: DNTH (Dianthus Therapeutics, Inc.) report within 7 days. Higher volatility risk.

Data coverage: 33.3% insider, 0.0% congressional, 100.0% earnings, 100.0% analyst, 66.7% news

Peer Analysis

Understanding how these stocks relate to their industry peers:

AMPX (Amprius Technologies, Inc.): Leads 8 peers: MVST ($2.09, -0.5%), ENR ($17.84, -2.4%), ENVX ($4.94, -3.0%), KMT ($38.04, -0.5%), NSP ($19.98, -8.9%) | Peer of: ATKR ($61.18, -0.7%), ATRO ($73.15, -1.6%), EAF ($5.63, +2.2%) and 8 more

CGON (CG Oncology, Inc.): Leads 10 peers: CELC ($117.10, +3.2%), AAPG ($24.49, +3.4%), CNTA ($27.59, +5.8%), APGE ($75.37, +0.6%), XENE ($60.61, -3.4%) | Peer of: AAPG ($24.49, +3.4%), APGE ($75.37, +0.6%), ARQT ($24.59, -0.9%) and 11 more

UAMY (United States Antimony Corporat): Leads 9 peers: GSM ($4.84, +5.5%), NEXA ($11.73, +4.7%), CMP ($23.48, -1.7%), SLI ($4.51, +1.4%), TMQ ($4.11, +2.5%) | Peer of: ASPI ($6.04, +4.0%), GSM ($4.84, +5.5%), NAK ($1.42, +5.2%) and 2 more

DNTH (Dianthus Therapeutics, Inc.): Leads 8 peers: ELVN ($30.24, +1.7%), TSHA ($4.57, -0.4%), SANA ($3.29, -1.2%), ATAI ($4.14, +6.4%), NKTR ($72.07, +4.2%) | Peer of: ANAB ($62.01, +3.9%), ATAI ($4.14, +6.4%), ELVN ($30.24, +1.7%) and 8 more

AGX (Argan, Inc.): Leads 8 peers: GVA ($124.47, -0.8%), MYRG ($267.90, +0.2%), ECG ($115.77, -0.3%), LSTR ($151.84, -0.6%), FELE ($94.77, -0.6%) | Peer of: ECG ($115.77, -0.3%), FELE ($94.77, -0.6%), GVA ($124.47, -0.8%) and 7 more

CAPR (Capricor Therapeutics, Inc.): Leads 10 peers: CABA ($3.32, +1.5%), LXEO ($7.20, -3.2%), PRQR ($1.80, -4.8%), TRDA ($13.20, +3.9%), IMMP ($2.76) | Peer of: ACHV ($4.28, +1.4%), CABA ($3.32, +1.5%), CADL ($5.11, -0.4%) and 11 more

Recent Headlines

AGX (Argan, Inc.)

• Argan (AGX) Soars 12.6%: Is Further Upside Left in the Stock? (source)
• Why Argan Stock Topped the Market Today (source)
• Taco Bell Parent, Data Center Play And Two Other Stocks Weather War Storm, Hover Near Highs (source)
• 3 Stocks With Explosive Potential That Could Transform Your Portfolio (source)

AMPX (Amprius Technologies, Inc.)

• Amprius Technologies (NYSE:AMPX) Trading Up 8.5% Following Analyst Upgrade (source)
• Amprius Stock Is Flashing One Signal That Traders Rarely Ignore (source)
• Amprius Technologies (NYSE:AMPX) Reaches New 1-Year High Following Analyst Upgrade (source)
• Is Amprius Technologies, Inc. (AMPX) Outperforming Other Business Services Stocks This Year? (source)
• Is Amprius Technologies, Inc. (AMPX) Outperforming Other Business Services Stocks This Year? (source)
• Amprius Technologies (NYSE:AMPX) Shares Up 18.6% Following Better-Than-Expected Earnings (source)
• Amprius Technologies (NYSE:AMPX) Shares Up 18.6% Following Better-Than-Expected Earnings (source)
• Why Amprius Technologies Stock Surged Today (source)
• Amprius Technologies, Inc. (AMPX) Q4 2025 Earnings Call Transcript (source)
• Amprius Stock Price Gets Amped by Hyper Growth Outlook (source)
• Amprius Technologies (AMPX) Reports Q4 Loss, Tops Revenue Estimates (source)
• Amprius Technologies Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Business Highlights (source)
• Amprius Sets March 2026 Events Schedule (source)

CAPR (Capricor Therapeutics, Inc.)

• What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday? (source)

CGON (CG Oncology, Inc.)

• CG Oncology (NASDAQ:CGON) vs. Adhera Therapeutics (OTCMKTS:ATRX) Critical Survey (source)
• CG Oncology Sees Unusually Large Options Volume (NASDAQ:CGON) (source)

Market Context

Current market conditions feature modest declines across major indices, with the S&P 500 down 0.17%, Nasdaq off 0.11%, and Dow Jones lower by 0.14%. The VIX's 2.21% rise to 24.93 signals elevated volatility, creating fertile ground for momentum swing strategies focused on volatile high beta assets. This environment amplifies intraday swings, enabling sharper momentum bursts and quicker reversals that align well with the strategy's emphasis on capturing short-term price extensions.

The mildly negative trend across benchmarks reflects cautious risk appetite, tempering bullish momentum but favoring tactical swings on both sides of the market. High beta positions, inherently sensitive to broader sentiment shifts, may experience exaggerated moves in this setup, rewarding disciplined entries on volatility spikes while heightening stop-loss discipline to manage drawdowns.

Healthcare's prominence among the six signals suggests sector rotation toward relatively resilient areas amid rising volatility. High beta components in this space could benefit from defensive flows combined with momentum dynamics, offering swing opportunities as investors rotate amid uncertain risk appetite.

Vlad's Take (EverHint)

Today's signals: Strong sector concentration in Healthcare (3 signals) suggests sector-specific rotation.

Sharing Call-to-Action

🎯 If this clarity helped your research, liking, sharing, or subscribing helps keep this project strong.

Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.

This is not financial advice. Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/